Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer

Objective: To observe bevacizumab plus chemotherapy curative effect and safety for recurrent and metastatic cervical cancer. Materials and Methods: Retrospective analysis of 30 recurrent and metastatic cervical cancer cases. The experimental group received bevacizumab plus paclitaxel-, docetaxel-, and platinum-based chemotherapy. The control group received only chemotherapy. Curative effects were recorded after at least two treatment cycles; adverse reactions were recorded with every cycle. Results: Experimental group patients were treated for an average 2.6 cycles. Compared to the control group, the experimental group effective rate (26.7%) was similar, disease control rate (73.7%) was significantly higher, and median survival time was three months longer. Bevacizumab-associated adverse reactions were bleeding, hypertension, and thrombosis/embolism; most were level 1 and 2 reactions. Adverse reactions in the two groups were not statistically different. Conclusions: The bevacizumab plus chemotherapy disease control rate for recurrent and metastatic cervical cancer is comparatively high, prolonging median survival; bevacizumab-associated adverse reactions are mild and tolerable.

Cervical neoplasms; Bevacizumab, Drug therapy, Targeted therapy, Drug toxicity.

[1] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D.: “Global cancer statistics”. CA Cancer J. Clin., 2011, 61, 69.

[2] Seol H.J., Ulak R., Ki K.D., Lee J.M.: “Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials”. Tohoku J. Exp. Med., 2014, 232, 269.

[3] Monk B.J., Sill M.W., McMeekin D.S., Cohn D.E., Ramondetta L.M., Boardman C.H., et al.: “Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2009, 27, 4649.

[4] Takekida S., Fujiwara K., Nagao S., Yamaguchi S., Yoshida N., Kitada F., et al.:“Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer”. Int. J. Gynecol. Cancer, 2010, 20, 1563.

[5] Zerbini G., Lorenzi M., Palini A.: “Tumor angiogenesis”. N. Engl. J. Med., 2008, 359, 763.

[6] Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al.: “Bevacizumab in combination with oxaliplatin, fluorouracil, and 1eucovorin(FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern cooperative Oncology Group study E3200”. J. Clin. Oncol., 2007, 25, 1539.

[7] Adjei A.A., Mandrekar S.J., Dy G.K., Molina J.R., Adjei A.A., Gandara D.R., et al.: “Phase
trial of pemetrexed plus Bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG Study N0426”. J. Clin. Oncol., 2010, 28, 614.

[8] Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al.: “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA openlabel randomized phase III trial”. J. Clin. Oncol., 2014, 32, 1302.

[9] Robert N.J., Dieras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., et a1.: “RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer”. J. Clin. Oncol., 2011, 29, 1252.

[10] Wright J.D., Viviano D., Powell M.A., Gibb R.K., Mutch D.G., Grigsby P.W., et al.: “Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer”. Gynecol Oncol., 2006, 103, 489.

[11] Tewari K.S., Sill M.W., Long H.J. 3rd, Penson R.T., Huang H., Ramondetta L.M., et al.: “Improved survival with bevacizumab in advanced cervical cancer”. N. Engl. J. Med., 2014, 370, 734.

[12] Monk B.J., Sill M.W., Burger R.A., Gray H.J., Buekers T.E., Roman L.D.: “Phase II Trial of Bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study”. J. Clin. Oncol., 2009, 27, 1069.

[13] Cassidy J., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., et al.: “XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results”. Br. J. Cancer, 2011, 105, 58.

[14] Van Meter M.E., Kim E.S.: “Bevacizumab: current updates in treatment”. Curr. Opin. Oncol., 2010, 22, 586.